体重指数与低强度运动类型对瑞加诺生副作用特征的影响
本研究纳入356例接受瑞加诺生负荷试验联合低强度运动的患者,按体重指数分为正常、超重和肥胖组,按运动方式分为平板步行组(TE组,190例)和坐位用力摆腿组(SS组,166例)。结果显示副作用发生率在各体重指数组间相似,但TE组面部潮红、头晕和恶心/胃肠道不适发生率显著低于SS组。结论认为瑞加诺生联合低强度运动在广泛体重指数范围内安全且耐受良好,TE运动的副作用特征优于SS。
要点
- 副作用发生率在各体重指数组间相似(p=ns)。
- TE组面部潮红、头晕和恶心/胃肠道不适发生率显著低于SS组(均p<0.05)。
- 各体重指数组间收缩压和心率无显著变化,TE组心率升高更明显(p<0.05)。
核心结论
- 瑞加诺生联合低强度运动在广泛体重指数范围内安全且耐受良好,TE运动的副作用特征优于SS。
研究设计与样本
- 纳入356例患者(男性46.1%,平均年龄67.7±10.7岁,范围31-90岁),接受瑞加诺生负荷试验联合低强度运动。
- 按体重指数分为正常、超重和肥胖组,按运动方式分为平板步行组(TE组,n=190)和坐位用力摆腿组(SS组,n=166)。
- 评估患者人口学特征、病史、负荷试验中临床症状、心电图变化、氧饱和度、收缩压和心率。
主要发现
- 各组心血管危险因素可比(p=ns)。
- 副作用发生率在各体重指数组间相似(p=ns)。
- TE组面部潮红发生率12.9% vs SS组28.4%,头晕19.9% vs 33.4%,恶心/胃肠道不适11.4% vs 19.2%(均p<0.05)。
- 各体重指数组间给药后收缩压和心率无显著变化。
- TE组与SS组比较,收缩压无显著变化,但TE组心率升高更明显(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Regadenoson, an A2A adenosine receptor pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI), is administered as a single, fixed dose. We studied the side effect profile of regadenoson combined with two types of low-level exercise, according to body mass index (BMI). METHODS: Three hundred and fifty-six patients (46.1% men, mean age 67.7±10.7 years, range 31-90 years) underwent regadenoson stress testing combined with low-level exercise. Subjects were classified according to BMI as normal, overweight, or obese, and the type of low-level exercise performed as walking on the treadmill (TE group, n=190) or forcefully swinging legs while sitting (SS group, n=166). Patients' demographics, medical history, clinical symptoms during stress, changes in ECG, oxygen saturation (SatO2), systolic blood pressure (SBP), and heart rate (HR) were evaluated. RESULTS: Groups were comparable (p=ns) with regard to cardiovascular risks factors. The incidence of side effects was similar across BMI (p=ns), although the TE patients showed improved profiles over those with SS exercise, with a significantly lower incidence of flushing, dizziness and nausea/gastrointestinal discomfort (12.9% vs. 28.4%; 19.9% vs. 33.4%; 11.4% vs. 19.2%, respectively; all p<0.05). Regarding the hemodynamic response, we did not observe significant changes in SBP and HR after regadenoson administration across BMI categories. Comparing the TE and SS groups, no significant changes were observed in SBP, but there was a higher increase in HR in the TE group (p<0.05). CONCLUSIONS: Regadenoson in combination with low-level exercise is safe and well tolerated over a wide range of BMI, with TE exercise showing a better side effect profile than SS.
引用
- Salgado-Garcia C, Jimenez-Heffernan A, Lopez-Martin J, et al. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson. Eur J Nucl Med Mol Imaging. 2017. PMID: 28547175. doi:10.1007/s00259-017-3717-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。